Stock LPTX LEAP THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
2.96 USD -1.33% Intraday chart for Leap Therapeutics, Inc. -4.98% -28.59%
Apr. 10 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI
Mar. 19 Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Number of employees: 54

Managers

Managers TitleAgeSince
Doug Onsi CEO
 Chief Executive Officer 55 10-12-31
Chris Mirabelli CHM
 Chairman 69 10-12-31
Jason Baum CTO
 Chief Tech/Sci/R&D Officer 45 20-08-23
Michael Haas CTO
 Chief Tech/Sci/R&D Officer - -
Cynthia Sirard CTO
 Chief Tech/Sci/R&D Officer 54 11-12-31
Augustine Lawlor COO
 Chief Operating Officer 67 15-12-31
Christine M. Granfield LAW
 General Counsel 56 20-08-23
Jonathan Miller PRN
 Corporate Officer/Principal - 19-12-31
Mark O’Mahony PRN
 Corporate Officer/Principal 53 10-12-31

Members of the board

Members of the board TitleAgeSince
Joseph Loscalzo BRD
 Director/Board Member 72 15-12-31
Nissim Mashiach BRD
 Director/Board Member 63 16-12-31
Chris Mirabelli CHM
 Chairman 69 10-12-31
James Cavanaugh BRD
 Director/Board Member 87 15-12-31
Thomas Dietz BRD
 Director/Board Member 60 15-12-31
Doug Onsi CEO
 Chief Executive Officer 55 10-12-31
Chris Richard BRD
 Director/Board Member 54 23-01-16
Patricia Martin BRD
 Director/Board Member 63 22-12-31
Richard Schilsky BRD
 Director/Board Member 73 22-08-31
William Li BRD
 Director/Board Member 61 16-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,600,137 24,797,892 ( 96.87 %) 0 96.87 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
4.579 %
1,172,175 4.579 % 3 M $
Adage Capital Partners GP LLC
3.683 %
942,918 3.683 % 3 M $
Rock Springs Capital Management LP
3.254 %
832,937 3.254 % 2 M $
BEIGENE LTD
2.870 %
734,844 2.870 % 2 M $
Citadel Securities GP LLC
2.667 %
682,749 2.667 % 2 M $
HealthCare Ventures LLC
2.642 %
676,321 2.642 % 2 M $
Samsara Biocapital LLC
2.614 %
669,303 2.614 % 2 M $
683 Capital Management LLC
1.758 %
450,000 1.758 % 1 M $
Vanguard Global Advisers LLC
1.601 %
409,804 1.601 % 1 M $
Acuta Capital Partners LLC
1.383 %
354,166 1.383 % 942 082 $

Company contact information

Leap Therapeutics, Inc.

47 Thorndike Street Suite B1-1

02141, Cambridge

+617 714 0360

http://www.leaptx.com
address Leap Therapeutics, Inc.(LPTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.96 USD
Average target price
11.75 USD
Spread / Average Target
+296.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEAP THERAPEUTICS, INC. Stock Leap Therapeutics, Inc.
-28.59% 75.79M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.07B
ARGENX SE Stock argenx SE
-1.08% 21.66B
BIONTECH SE Stock BioNTech SE
-18.35% 20.77B
GENMAB A/S Stock Genmab A/S
-8.12% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LPTX Stock
  4. Company Leap Therapeutics, Inc.